Parkinson’s disease biology, and DRD1 gene modulation, focused on supporting dopaminergic signaling in Parkinson’s and related movement-disorder settings.

Pathways is building a disciplined, capital-efficient development model that integrates translational biology, biomarker strategy, regulatory planning, CMC readiness, and strategic partnering to advance differentiated gene-based therapeutic programs toward patient-enabling milestones.